[HTML][HTML] Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Results Among 764 non-squamous NSCLC cases with known EGFRm status, 26 (3.4%)
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - …, 2017 - research.unipd.it
Introduction: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-
small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth …
small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth …
[PDF][PDF] Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - academia.edu
ABSTRACT Introduction: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for
advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 …
advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 …
[PDF][PDF] Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - pdfs.semanticscholar.org
ABSTRACT Introduction: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for
advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 …
advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 …
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Introduction Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-
small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth …
small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth …
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - europepmc.org
Results Among 764 non-squamous NSCLC cases with known EGFRm status, 26 (3.4%)
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …
[HTML][HTML] Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - oncotarget.com
Abstract Stefano Frega 1, 6,*, Martina Lorenzi 1,*, Matteo Fassan 2, Stefano Indraccolo 3,
Fiorella Calabrese 4, Adolfo Favaretto 5, Laura Bonanno 6, Valentina Polo 1, 6, Giulia Zago …
Fiorella Calabrese 4, Adolfo Favaretto 5, Laura Bonanno 6, Valentina Polo 1, 6, Giulia Zago …
[引用][C] Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - cir.nii.ac.jp
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with
uncommon or complex epidermal growth factor receptor (EGFR) mutations | CiNii Research …
uncommon or complex epidermal growth factor receptor (EGFR) mutations | CiNii Research …
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - oncotarget.com
Abstract Stefano Frega 1, 6,*, Martina Lorenzi 1,*, Matteo Fassan 2, Stefano Indraccolo 3,
Fiorella Calabrese 4, Adolfo Favaretto 5, Laura Bonanno 6, Valentina Polo 1, 6, Giulia Zago …
Fiorella Calabrese 4, Adolfo Favaretto 5, Laura Bonanno 6, Valentina Polo 1, 6, Giulia Zago …
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) …
S Frega, M Lorenzi, M Fassan, S Indraccolo… - Oncotarget, 2017 - europepmc.org
Results Among 764 non-squamous NSCLC cases with known EGFRm status, 26 (3.4%)
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …
harboured rare/complex EGFRm. Patients receiving first-line TKIs (N= 17) achieved median …